AYTU BIOPHARMA, INC
AYTU · XNASCIK 1385818fmd_0DGD15AK1ME9Z7JXWA2A9RWZRQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Mar 01, 2005 to Jun 30, 2026, 74 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 4 | 7 | 28 | 66 | 97 | 107 | 65 | 66 | 58 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Cost of revenue | 1 | 2 | 2 | 8 | 36 | 44 | 41 | 16 | 21 | 21 |
| Gross profit | 2 | 2 | 5 | 19 | 29 | 52 | 67 | 49 | 46 | 37 |
| Realized investment gains (losses) | (0) | – | – | – | – | – | – | – | – | – |
| Research and development | 1 | 0 | 1 | 2 | 6 | 13 | 4 | 3 | 1 | 0 |
| Selling, general and administrative | 17 | 18 | 19 | 31 | 56 | 70 | 70 | 42 | 38 | 43 |
| Total operating expenses | 23 | 23 | 24 | 40 | 88 | 162 | 84 | 51 | 54 | 45 |
| Operating income | (20) | (20) | (17) | (21) | (59) | (110) | (17) | (2) | (8) | (8) |
| Interest expense | 3 | 1 | 1 | 3 | – | 1 | 5 | 5 | 4 | 2 |
| Other non-operating income (expense) | (2) | 10 | (10) | 8 | 1 | 1 | 0 | 1 | (1) | 1 |
| Income before taxes | – | – | – | (14) | (58) | (109) | (17) | (10) | (14) | (14) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | (0) | 0 | 2 | 0 | 0 |
| Net income from continuing operations | – | – | – | (14) | (58) | (109) | (17) | (13) | (14) | (14) |
| Net income | (23) | (10) | (27) | (14) | (58) | (109) | (17) | (16) | (14) | (14) |